CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus 中国心力衰竭诊断和治疗指南2018

Clinical Trial2021 Jan 26;143(4):310-321.

JOURNAL:Circulation. Article Link

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

F Zannad, JP Ferreira, SJ Pocock et al. Keywords: empagliflozin; glomerular filtration rate; heart failure; renal insufficiency; chronic

Full Text PDF